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Lenalidomide at a dose of 10 mg daily is approved for treatment of low risk/intermediate risk-1 myelodysplasia (MDS) patients who are red cell transfusion dependent. 1, 2 We recently reported on an institutional phase 2 trial treating newly diagnosed elderly acute myeloid leukemia (AML) patients with high-dose single agent lenalidomide as an induction treatment (50 mg/day Â 28 days) followed by lower dose maintenance (10 mg daily for 12 months). Thirty percent of patients achieved a complete remission (CR) or complete remission with incomplete blood count recovery (CRi) of 30%. 3, 4 We and others have hypothesized that the combination of lenalidomide and azacitidine (AZA) may result in higher rates of sustained CR compared with these drugs individually. Sekeres et al. 5 showed feasibility and efficacy of low-dose lenalidomide (10 mg daily) with AZA in high-risk MDS. We read the article 'Safety, efficacy and biological predictors of response to sequential AZA and lenalidomide for elderly patients with acute myeloid leukemia' by Pollyea et al. 6 with interest. In that article, the authors report their experience with a phase 1 trial using sequential therapy with AZA and lenalidomide for elderly patients with AML. In the trial, the authors escalated the dose of lenalidomide to 50 mg/day with AZA dose fixed at 75 mg/m 2 . Here we report on the findings of our own institutional phase 1 prospective trial of AZA and high-dose lenalidomide (HDL) as an induction regimen followed by maintenance therapy with standard dose AZA and lower dose of lenalidomide. In contrast to Pollyea et al., 6 we (1) used escalating doses of AZA while keeping the lenalidomide dose constant, (2) used concomitant dosing of AZA and HDL and (3) chose to reduce the dose of lenalidomide after the initial two cycles of therapy.
Newly diagnosed elderly AML patients X60 years of age with intermediate-or poor-risk cytogenetics, without isolated 5q abnormalities (elderly AML) and relapsed/refractory AML X18 years of age (relapsed AML) were eligible for this study. Additional inclusion criteria included: Eastern Cooperative Oncology Group performance status of 0-2, and adequate renal (serum creatinine o1.5 Â upper limit of normal) and hepatic function (bilirubin o2.0 mg/dl and aspartate aminotransferase/ alanine transaminase o5 Â upper limit of normal). Patients with acute promyelocytic leukemia, central nervous system leukemia, or prior use of lenalidomide or AZA were excluded. The treatment schedule consisted of two 28-day induction cycles with HDL, 50 mg orally for days Letters to the Editor orally for days 1-28 and AZA 75 mg/m 2 intravenously for days 1-5 intravenously for up to 12 cycles. Lenalidomide and AZA were provided by the manufacturer (Celgene Corporation, Summit, NJ, USA). All patients except those with progressive disease after the two induction cycles continued with the maintenance cycles. Induction cycles were not interrupted nor were doses modified for expected hematological toxicities, but therapy could be interrupted for febrile neutropenia, grade X3 nonhematological toxicities or bone marrow aplasia. During maintenance cycles, doses were delayed or reduced for febrile neutropenia, grade X3 and prolonged hematological toxicities. Patients continued to receive maintenance cycles until an unacceptable adverse event or disease progression. Growth factors were not administered routinely but were allowed as clinically indicated. Response was assessed by bone marrow biopsy and complete blood count at the completion of induction cycles 1 and 2, after completion of maintenance cycles 2, 4, 6 and 12 and as clinically indicated during maintenance therapy. All adverse events were evaluated and coded using the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0. Responses were assessed using the International Working Group criteria. 7 The primary endpoint was to determine the maximum tolerated dose (MTD) and toxicity profile.
A total of 19 patients were enrolled in the study ( Table 1 ). The median age was 72 years (range 63-81); 9 males (47.4%), 10 females (52.6%); 10 (52.6%) with newly diagnosed elderly AML and 9 (47.4%) with relapsed or refractory AML. The median WBC count was 2200 Â 10 9 cell/l (range 800 Â 10 9 -20 900 Â 10 9 cell/l). The median bone marrow blast percentage was 23% (range 2-81%). Cytogenetics showed a normal karyotype in 8 (42.1%), a complex karyotype in 4 (21.1%), monosomy 7/del 7q in 3 (15.7%), trisomy 8 in 1 (5.2%) and other clonal abnormalities in 3 (15.7%). Patients in each cohort who did not complete one induction cycle were replaced. In all, 13 (68.4%) patients completed at least one 
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Letters to the Editor induction cycle, 11 (57.9%) patients completed two induction cycles and 8 (42.1%) patients went on to receive maintenance therapy. Patients remained on therapy for a median of 77 days (range 0-566). Dose-limiting toxicities (DLT) observed included grade 3 rash in cohort 1 leading to expansion of the cohort to include three additional patients (Table 2) . To date, grade 3/4 non-DLT hematological toxicity was seen in 12 (92.3%) out of 13 patients. The most common 3/4 non-DLT hematological toxicity was thrombocytopenia seen in 10 (76.9%) out of 13 patients. The most common grade 1/2 toxicity was fatigue in 6 (42.9%) out of 14. None of the 6 patients in cohort 3 developed DLT, and hence the MTD was not reached in this study. Of the 13 patients, 7 (53.8%) patients have died, all owing to treatment failure due to resistant disease. Of the 13 evaluable patients, 7 (53.8%) responded to treatment, with CR/CRi in 4 (30.8%) and partial remission in 3 (23.1%), with a median duration of response is 3 months (range 1-17).
Our data complements the findings of Pollyea et al. 6 and demonstrates that the combination of HDL and AZA sequentially or concomitantly is well tolerated. The best strategy for postinduction treatment with these agents should be explored further. Reducing to low-dose lenalidomide after the induction phase may reduce the potential for myelosuppression. The continuing phase 2 expansion cohorts of both studies should provide additional information on this issue.
The proportion of CD34
þ CD38 low or neg myeloblasts, but not side population frequency, predicts initial response to induction therapy in patients with newly diagnosed acute myeloid leukemia Normal hematopoiesis is sustained by a relatively small pool of self-renewing primitive hematopoietic stem cells (HSCs). In murine hematopoietic repopulation studies, human cells with bright expression of CD34, but no expression of CD38, are highly enriched in HSC activity.
1 Cells with similar immunophenotype are implicated as leukemia stem cells (LSCs), 2 the initiating and repopulating reservoir for acute myeloid leukemia (AML). CD34 þ CD38 neg cell frequency at diagnosis correlates with the incidence of minimal residual disease following achievement of complete remission (CR) in adult AML 3 and with worse event-free survival in pediatric AML. 4 A similar, but not identical, population of cells known as 'side population' (SP) has been defined based on ability to efflux fluorescent dye Hoechst 33342 via the ABCG2 multidrug resistance-mediating transporter that can be inhibited by fungal toxin Fumitremorgin C (FumC). 5 The SP was originally characterized in mice 6 and was demonstrated to contain primitive HSCs. The stem cell reservoir in nearly all normal tissues resides in the SP, 7 and it also contains the primitive stem cells for solid tumors, including breast, prostate and lung cancer. [8] [9] [10] The relationship between SP and CD34 þ CD38 dim cells has not been previously explored in AML. Three studies demonstrated that SP could be isolated from AML patients. The first study of 16 patients showed that presence of the SP was not related to expression of the multidrug resistance gene (MDR-1), expressed variable CD38, was present with different types of cytogenetics abnormalities, and variably engrafted immunodeficient mice.
11
The second study demonstrated that the SP was present in 80% of 61 patients, that 3 out of 28 cases could engraft NODscid mice and that 11/11 exhibited abnormal cytogenetics. 12 The third study highlighted the heterogeneity of the SP derived from 48 patients, although there was uniform expression of the stem cell marker CLL-1. 13 LSCs appear to provide a reservoir for relapse of AML following chemotherapy.
14 Chemoresistance may reflect the relative quiescent state of the LSC and/or increased expression of drug efflux mediating transporters that extrude chemotherapy drugs. 15 The latter possibility motivated us to determine whether SP correlated with outcome in AML. In particular, we investigated the relationship between the frequencies of CD34 þ CD38 neg , CD34 þ CD38 low and SP blasts and clinical prognostic variables, such as age, cytogenetics, achievement and duration of first CR, in patients with newly diagnosed AML.
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